For decades, millions of women dusted their bodies with a powder they trusted, unaware that the mineral at its heart would one day be classified as probably carcinogenic by the World Health Organization. Johnson & Johnson, one of the world's most recognizable consumer brands, has now agreed to pay $5.5 billion to settle nearly 70,000 American lawsuits alleging its talc-based baby powder caused ovarian cancer — a sum that speaks less to admitted guilt than to the accumulated weight of human suffering and courtroom reckoning. The settlement, contingent on approval from 95 percent of claimants, w
J&J Agrees to $5.5B Talc Settlement Covering Nearly 70,000 US Cases
Thousands of individuals developed ovarian cancer and mesothelioma allegedly linked to talc product exposure, resulting in deaths and serious illness.
The cost of proving itself right in 70,000 trials became too high
Mark
Why did it take a decade of lawsuits before J&J settled? If the science was unclear, why not fight harder?
Mimi
The company did fight. But juries kept ruling against them. At some point, the math changes—legal fees, insurance costs, reputational damage, and the sheer volume of cases make settlement cheaper than continued litigation.
Mark
But J&J still says talc doesn't cause cancer. How do you settle a case you claim you didn't lose?
Mimi
You don't admit you lost. You settle to end uncertainty. The company never conceded the science. It just decided the cost of proving itself right in 70,000 separate trials was too high.
Mark
What about the women who used the product? Does this settlement actually compensate them fairly?
Mimi
That depends on how the $5.5 billion gets divided among 70,000 claimants. Some will receive more, some less. The real question is whether the amount reflects the actual harm—the illness, the medical costs, the loss of life.
Mark
The UK case is still pending. Could that change how we understand what J&J knew?
Mimi
Possibly. The UK case explicitly alleges the company knew about the risks. If that's proven, it reframes the entire history—from a scientific dispute into a question of corporate knowledge and choice.
Mark
Does settling in the US help J&J in the UK?
Mimi
Not necessarily. It might even hurt. A settlement can be read as an admission of liability in some jurisdictions, or it can be used as evidence that the company understood the risk well enough to pay billions to make it go away.
Il Polso
- Nearly 70,000 people — most of them women who developed ovarian cancer or mesothelioma — have spent years in legal battle against one of the world's most powerful consumer health companies.
- A 2016 jury verdict awarding $72 million to one family cracked open a floodgate, and subsequent verdicts across the country turned individual tragedies into a coordinated legal siege that cost J&J billions before any settlement was reached.
- J&J quietly pulled talc powder from US shelves in 2020 and from global markets in 2023, a commercial retreat that sat uneasily beside the company's continued insistence that no credible evidence linked its product to cancer.
- The $5.5 billion deal is framed by the company as a way to move forward, but it hinges on a 95 percent claimant approval threshold — meaning the litigation is not yet over, and thousands of individuals still hold the outcome in their hands.
- Across the Atlantic, more than 7,000 UK claimants are pursuing what is described as the largest product liability case in British legal history, alleging not just harm but knowing misconduct — a charge that could redefine the company's legacy far beyond any American settlement.
For decades, millions of women dusted their bodies with a powder they trusted, unaware that the mineral at its heart would one day be classified as probably carcinogenic by the World Health Organization. Johnson & Johnson, one of the world's most recognizable consumer brands, has now agreed to pay $5.5 billion to settle nearly 70,000 American lawsuits alleging its talc-based baby powder caused ovarian cancer — a sum that speaks less to admitted guilt than to the accumulated weight of human suffering and courtroom reckoning. The settlement, contingent on approval from 95 percent of claimants, would close nearly all outstanding US litigation, though a parallel case in the UK, involving over 7,000 claimants and allegations of knowing misconduct, reminds us that some reckonings do not end with a single payment.
Johnson & Johnson announced it will pay $5.5 billion to resolve nearly 70,000 US lawsuits alleging that its talc-based baby powder caused ovarian cancer in women who used the product over many years. If approved by at least 95 percent of claimants in both state and federal courts, the settlement would close 99.75 percent of all outstanding talc litigation in the United States — the culmination of more than a decade of legal battles.
Talc, once a staple of nurseries and bathroom cabinets worldwide, has faced deepening scientific scrutiny. The World Health Organization classified it as probably carcinogenic in 2024. J&J has consistently denied any cancer link, yet discontinued its talc powder in the US in 2020 and globally by 2023 — a quiet commercial withdrawal that many observers read as an acknowledgment of risk, even without a legal admission.
The litigation's turning point came in 2016, when a jury ordered J&J to pay $72 million to the family of a woman who died of ovarian cancer. Though that verdict was later overturned, it opened the door to a wave of cases. Juries increasingly sided with plaintiffs, and the mounting verdicts made settlement a rational calculation for the company. J&J's litigation chief described the deal as a way to put the matter behind it; plaintiff attorneys called it a hard-won victory after years of struggle.
The settlement's finality is not yet guaranteed — the 95 percent approval threshold leaves some uncertainty. And beyond US borders, a far more pointed legal challenge awaits. A case filed in the UK High Court in October 2025, involving more than 7,000 claimants, alleges that J&J knowingly sold a product it understood could cause cancer. Described as the largest product liability litigation in British history, it carries accusations of deliberate misconduct that no settlement figure can easily put to rest.
Johnson & Johnson announced on Monday that it will pay $5.5 billion to settle nearly 70,000 lawsuits across US federal and state courts. The cases allege that the company's talc-based baby powder caused ovarian cancer in women who used the product over decades. The settlement, if approved by at least 95 percent of claimants, would resolve 99.75 percent of all outstanding talc-related litigation in the country—a staggering volume of claims that accumulated over more than a decade of courtroom battles.
Talc, a soft mineral once ubiquitous in cosmetics and baby care products, has faced mounting scrutiny as evidence of potential health risks accumulated. The World Health Organization classified it as "probably carcinogenic to humans" in 2024, a designation that reflected years of scientific concern. Despite this, Johnson & Johnson has consistently maintained that no credible evidence links talc to cancer. Yet the company discontinued its talc-based baby powder in the United States in 2020 and worldwide by 2023, a move that suggested commercial caution even as legal liability mounted.
The litigation began in earnest after a 2016 jury verdict ordered Johnson & Johnson to pay $72 million to the family of a woman who died of ovarian cancer allegedly caused by talc exposure. Though that initial verdict was overturned a year later, it opened a floodgate. Subsequent juries across the country sided with plaintiffs with increasing frequency, awarding damages in case after case. Each verdict added pressure and cost, making settlement an increasingly rational business decision for the company.
Erik Haas, Johnson & Johnson's head of litigation, framed the settlement as a way to "put this matter behind it"—language that captured the company's desire to move past years of courtroom exposure and financial uncertainty. Lawyers representing the plaintiffs characterized the deal as a meaningful victory after a decade-long struggle, suggesting that while the company never admitted wrongdoing, the settlement amount reflected the weight of accumulated evidence and jury verdicts.
The settlement's finality remains conditional. It requires approval from 95 percent of claimants in both state and federal courts, a threshold that introduces uncertainty into what otherwise appears to be a done deal. Until that approval materializes, the litigation technically continues.
Meanwhile, Johnson & Johnson faces a separate and potentially more consequential legal battle in the United Kingdom. Filed in October 2025, a case involving more than 7,000 potential claimants is now before the UK High Court. The British litigation alleges that Johnson & Johnson knew talc could cause ovarian cancer and mesothelioma but continued selling the product anyway—a claim of knowing misconduct rather than mere product defect. The company denies this allegation as well. The UK case, described as the largest product liability litigation in British history, remains unresolved and could reshape how the company's conduct is viewed internationally.
Citazioni salienti
The agreement allows the company to put this matter behind it— Erik Haas, Johnson & Johnson litigation head
Plaintiffs' lawyers welcomed the settlement as a good resolution to a decade-long court battle— Lawyers representing plaintiffs
Vuoi la storia completa?
Leggi l'originale su Al Jazeera ↗
Health & Medicine